Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Insider Selling Spree Rattles MACOM Investors Ahead of Earnings

Dieter Jaworski by Dieter Jaworski
November 1, 2025
in Earnings, Insider Trading, Semiconductors
0
Macom Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

MACOM Technology Solutions shares are facing significant pressure following substantial stock sales by a major shareholder just days before the company’s quarterly results announcement. The timing of these transactions has sparked concern among market participants.

Leadership Transition and Massive Stock Disposal

Former director Susan Ocampo executed sales totaling over $18 million during two consecutive trading days last week. She divested 132,873 shares at prices ranging from $148.02 to $150.01 per share. Market reaction was immediate, with the stock declining to $150.61, retreating from its recent all-time peak of $152.66.

This development follows Ocampo’s recent departure from the board of directors in late August after fifteen years of service. The convergence of leadership changes and substantial insider selling has created uncertainty throughout the investment community.

Financial Performance and Forward Guidance

Concurrent with these transactions, MACOM released earnings guidance for the fourth quarter. The company projects earnings per share between $0.910 and $0.950. This forecast builds upon a robust third-quarter performance where MACOM exceeded expectations with EPS of $0.90 against projections of $0.89.

Should investors sell immediately? Or is it worth buying Macom?

Revenue showed impressive momentum, climbing 32.3% year-over-year to reach $252.08 million. However, questions remain about whether this growth trajectory sufficiently supports current valuation levels.

Market Analysts Express Divergent Views

Research analysts maintain mixed perspectives on MACOM’s outlook. While the consensus rating stands at “Moderate Buy,” price targets display considerable variation from $136 to $155 per share. TD Cowen recently highlighted growth opportunities in key sectors including electronic warfare systems, radar technology, and data center infrastructure.

Technical indicators now suggest potential headwinds. After reaching record highs, the stock is showing early signs of exhaustion. All eyes turn to Thursday’s quarterly earnings release, which will prove crucial in determining whether the company can restore confidence following the unsettling insider sales activity.

Ad

Macom Stock: Buy or Sell?! New Macom Analysis from February 7 delivers the answer:

The latest Macom figures speak for themselves: Urgent action needed for Macom investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Macom: Buy or sell? Read more here...

Tags: Macom
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock
Analysis

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Next Post
Outfront Media Stock

High-Yield Opportunity: Outfront Media Shares Offer 7% Dividend

C3.ai Stock

C3.ai Shares Plunge Amidst Financial Turmoil and Leadership Shakeup

Redcare Pharmacy Stock

Redcare Pharmacy Shares Tumble Despite Record Performance

Recommended

Jakks Pacific Reports Disappointing Q4 2023 Earnings

2 years ago
Ecommerce Stock Exchange

Notable Options Market Activity for Shopify

2 years ago
Fannie Mae Stock

Fannie Mae’s Public Offering Plans Derailed by Prominent Investor

3 months ago
Ocugen Stock

Ocugen Shares Face Critical Test Amid Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

by Rodolfo Hanigan
February 7, 2026
0

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The...

Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves
  • Deluxe Stock Gains Momentum on Successful Fintech Transition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com